We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Merck & Co., Inc. Licenses SNALP Technology from Protiva

News   Oct 18, 2007

 
Merck & Co., Inc. Licenses SNALP Technology from Protiva
 
 
 

RELATED ARTICLES

Embryonic Stem Cells Commit to Their Fate Earlier Than First Thought

News

This study challenges the longstanding assumption that embryonic stem cells remain quite plastic and malleable during the earliest stages of cell commitment.

READ MORE

The "Midlife Crisis" of Molecular Aging

News

Key molecular programs known to promote longevity do not last beyond midlife, according to a study of genomic patterns in human muscle and brain tissue. The study suggests a possible explanation for why the human disease burden increases so sharply from the sixth decade of life.

READ MORE

tRNA a Warning System for Oncoming Epileptic Seizures?

News

Changes in the concentration of specific transfer RNAs, a major class of noncoding RNA, are associated with epilepsy. The findings suggest that tRNA fragments could serve as an early warning system for predicting seizure risk.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE